I'm working on a round-up article for MedCentral on available therapies for MASH with a focus on the MASH pharmacotherapy pipeline. For this, I'm looking for a hepatologist or liver disease specialist to offer expert insights and perspective. Deadline is Tuesday 04/21 EOD. Questions: 1. What are your thoughts on effective available/FDA-approved therapies as well as emerging therapies within the MASH pharmacological landscape? FGF21 analogues 2. How do you see the FGF21 analog class (efruxifermin, pegozafermin, efimosfermin) differentiating itself in MASH, particularly on steatosis, fibrosis, and other metabolic parameters, and which agent currently stands out as the most promising? GLP‑1/GIP‑based agents 3. For GLP‑1/GIP incretin‑based agents (survodutide, tirzepatide, retatrutide, pemvidutide) in MASH, how much of the observed benefit do you think is driven by weight loss versus direct hepatic effects, and what makes one agent stand-out clinically over another in a liver‑focused indication? Lanifibranor, VK2809, belapectin, denifanstat, ervogastat 4. Among lanifibranor, VK2809, belapectin, denifanstat, and ervogastat, which mechanism do you think has the strongest potential to deliver a clinically meaningful MASH benefit, and what are the key gaps in data or safety that still need to be addressed before any of these agents becomes a routine treatment option? 5. Looking ahead, how do you see the MASH pharmacological pipeline evolving over the next 5–10 years, particularly in terms of combination approaches, positioning versus invasive disease endpoints, and which mechanisms can we expect to become first‑line or add‑on therapies?